The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials

In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA). This post-hoc analysis assessed the VE against HZ and postherpeti...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Joon Hyung Kim, John Diaz-Decaro, Ning Jiang, Shinn-Jang Hwang, Eun Ju Choo, Maribel Co, Andrew Hastie, David Shu Cheong Hui, Junya Irimajiri, Jacob Lee, Edward Man-Fuk Leung, Haiwen Tang, Tomomi Tsuru, Philip Watson, Zhenhua Wu, Chong-Jen Yu, Yanfei Yuan, Toufik Zahaf, Anthony L. Cunningham, Anne Schuind
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Taylor & Francis Group 2021-07-01
Sarja:Human Vaccines & Immunotherapeutics
Aiheet:
adjuvanted recombinant zoster vaccine
herpes zoster
postherpetic neuralgia
efficacy
safety
asian population
Linkit:http://dx.doi.org/10.1080/21645515.2020.1859321

Internet

http://dx.doi.org/10.1080/21645515.2020.1859321

Samankaltaisia teoksia